Factors associated with survival in a contemporary adult sickle cell disease cohort

American Journal of Hematology

Volumn 89, Issue 5, 2014, Pages 530-535

  Elmariah, Hany ^a   Garrett, Melanie E ^a   De Castro, Laura M ^a   Jonassaint, Jude C ^a   Ataga, Kenneth I ^b   Eckman, James R ^c   Ashley Koch, Allison E ^a   Telen, Marilyn J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIMIGRAINE AGENT; BRONCHODILATING AGENT; CELL ADHESION MOLECULE; DEFEROXAMINE MESYLATE; HEMOGLOBIN; HEMOGLOBIN S; HYDROXYUREA; IRON CHELATING AGENT; NARCOTIC AGENT; PARACETAMOL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ADULT DISEASE; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GENOTYPE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; PULMONARY HYPERTENSION; SEIZURE; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; SICKLE CELL CRISIS; SURVIVAL; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, SICKLE CELL; COHORT STUDIES; COMORBIDITY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SOUTHEASTERN UNITED STATES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84898429927     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23683     Document Type: Article

References (36)

1. Diggs LM. Anatomic lesions in sickle cell disease. In: Sickle cell disease: diagnosis, management, education, and research. Abramson H, Bertles JF, Wethers DL, eds. C.V. Mosby (St. Louis), 1973:189-229.
2. Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Cooperative study of sickle cell disease. Pediatrics 1989;84:500-508.
3. Davis H, Schoendorf K, Gergen P, et al. National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health 1997;87:1317-1322.
4. Centers for Disease Control and Prevention. Mortality among children with sickle cell disease identified by newborn screening during 1990-1994: California, Illinois, and New York. JAMA 1998;279:1059-1060.
5. Quinn C, Rogers Z, Buchanan G. Survival of children with sickle cell disease. Blood 2004;103:4023-4027.
6. Platt O, Brambilla D, Rosse W, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
7. Steinberg M, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651.
8. Johnson C, Telen MJ. Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease Haematoligica 2008;93:481-486.
9. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011;118:19-27.
10. Gee B. Sickle reticulocytes adhere to VCAM-1. Blood 1995;85:268-274.
11. Telen MJ. Role of adhesion receptors molecules and vascular endothelium in the pathogenesis of sickle cell disease. Hematology 2007:84-90.
12. Kaule D, Liu X-D, Zhang X, et al. Peptides based on αV-binding domains of erythrocyte ICAM-4 inhibit sickle red cell-endothelial interactions and vaso-occlusion in the microcirculation. Am J Physiol Cell Physiol 2006;C922-C930.
13. Zennadi R, Moeller B, Whalen E, et al. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood 2004;10:2708-2717.
14. Zennadi R, Hines P, DeCastro L, et al. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-αVβ3 interactions. Blood 2004;104:3774-3781.
15. Okpali I, Daniel Y, Haynes R, et al. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur J Haematol 2002;69:135-144.
16. Fadlon E, Vordermeier S, Pearson T, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 1998;91:266-274.
17. Finnegan E, Turhan A, Golan D, et al. Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion. Am J Hematol 2007;82:266-275.
18. Turhan A, Weiss L, Mohandas N, et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm. Proc Natl Acad Sci USA 2002;99:3047-3051.
19. Brown M, Wick T, Eckman J. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med 2001;20:47-72.
20. Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997;337:1584-1590.
21. Styles L, Lubin B, Vichinsky E, et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997;89:2554-2559.
22. Covas D, de Lucena A, Vianna Bonini Palma P, et al. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. Haematoligica 2004;89:273-280.
23. Brun M, Bourdoulous S, Couraud P, et al. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J 2003;3:215-226.
24. Adam S, Jonassaint J, Kruger H, et al. Surgical and obstetric outcomes in adults with sickle cell disease. Am J Med 2008;121:916-921.
25. Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: Association with hemolysis and hemoglobin oxygen desaturation. Haematologica 2009;94:340-347.
26. Afenyi-Annan A, Kail M, Combs M, et al. Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion 2008;48:917-924.
27. Fitzhugh CD, Lauder N, Jonassaint JC, et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol 2009;85:36-40.
28. Levey A, Berg R, Gassman J, et al. Creatinine filtration, secretion and excretion during progressive renal disease. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int Suppl 1989;27:S273-S280.
29. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010;85:403-408.
30. Gladwin M, Sachdev V, Jison M, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
31. Florence Parent MD, Dora Bachir MD, Jocelyn Inamo MD, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44-53.
32. Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: A 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005;84:363-376.
33. Kato G, Martyr S, Blackwelder W, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol 2005;130:943-953.
34. McClish D, Penberthy L, Bovbjerg V, et al. Health related quality of life in sickle cell patients: The PiSCES project. Health Qual Life Outcomes 2005;3:50. http://www.hqlo.com/content/3/1/50.
35. Kauf T, Coates T, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009;84:323-327.
36. Hsieh M, Kang E, Fitzhugh C, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009;361:2309-2317.